Page last updated: 18 January 2017


Post-market Reviews of Pharmaceutical Benefits Scheme Subsidised Medicines

The Government has introduced a systematic post-market approach to monitoring medicines in use to inform decision making at all levels throughout the medicine cycle (from the registration of a medicine right through to its use by consumers). More information can be found at:


Post-market Review of Pulmonary Arterial Hypertension (PAH) Medicines


Post-market Review of the use of biologics in the treatment of severe chronic plaque psoriasis


Post-market Review of Chronic Obstructive Pulmonary Disease (COPD) Medicines


Post-market Review of Ezetimibe


Post-market Review of Authority Required Pharmaceutical Benefits Scheme Listings


Post-market Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease


Review of Anticoagulation Therapies in Atrial Fibrillation


Post-market Review of Pharmaceutical Benefits Scheme Medicines to Treat Asthma in Children


Post-market Review of Products Used in the Management of Diabetes


12 Month Review of the Introduction of Streamlined Authorities

The report on the review of the first 12 months of operations of the PBS Streamlined Authorities, which were introduced to reduce the administrative burden for prescribers and allow them more time to devote to patient care.


Review of Pharmacy Remuneration and Regulation


Post-market Review of the Life Saving Drugs Program


Independent Review (PBS)


Independent Review of the Impact of PBS Cost Recovery


Pharmaceutical Benefits Advisory Committee Guidelines Review


Working together to improve the Pharmaceutical Benefits Scheme: Review of Post PBAC Processes Report (2004)